Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial - Concepedia

Concepedia

Publication | Open Access

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

DOI Full Paper Access

174

Citations

15

References

2022

Year

Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiufeng Liu, Juxiang Xiao,

Journal of Clinical Oncology

Abstract

In patients from Asia with previously treated advanced HCC, pembrolizumab significantly prolonged overall survival and PFS, and ORR was greater versus placebo.

References

	Year	Citations

Page 1